## **OncoTargets and Therapy**

Open Access Full Text Article

RETRACTION

# MicroRNA-939 Directly Targets HDGF to Inhibit the Aggressiveness of Prostate Cancer via Deactivation of the WNT/ $\beta$ -Catenin Pathway [Retraction]

Situ J, Zhang H, Jin Z, Li K, Mao Y, Huang W. Onco Targets Ther. 2020;13:4257–4270.

The Editor and Publisher of *OncoTargets and Therapy* wish to retract the published article. Concerns were raised over alleged image duplication in Figure 8A with similar images from unrelated articles, specifically:

• Figure 8A appears to have been duplicated with a similar image in Figure 6A from Chen et al, 2019 (https://doi.org/10.3892/ijmm.2019.4429).

The authors did not respond to our queries and the Editor determined the findings of the study were no longer valid and advised for the article to be retracted.

Our decision-making was informed by our policy on publishing ethics and integrity and the COPE guidelines on retraction.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as "Retracted".

#### **OncoTargets and Therapy**

### **Dove**press

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/ testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/oncotargets-and-therapy-journal

https://doi.org/10.2147/OTT.\$341951

Received: 29 September 2021 Accepted: 29 September 2021 Published: 5 October 2021

#### OncoTargets and Therapy 2021:14 5001

500 I

© 2021 Dove Medical Press. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/ the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).